Genome-wide association study reveals the unique genetic structure of active blood donors

Jonna Clancy^{*1}, Jarkko Toivonen¹, Jouni Lauronen¹, Satu Koskela¹, Jukka Partanen¹, FinnGen², Mikko Arvas¹, Jarmo Ritari¹

- ¹ Finnish Red Cross Blood Service, Vantaa, Finland
- ² List of FinnGen members is available as a supplementary file

* jonna.clancy@veripalvelu.fi

1 Abstract

3	The healthy donor effect (HDE) refers to the observed lower mortality rate among blood donors
4	compared to the general population. While membership biases such as HDE arise due to healthier
5	individuals being more likely to participate, the extent to which it is influenced by genetic differences
6	remains largely unclear. To elucidate the genetic basis of HDE, we conducted a genome-wide
7	association study (GWAS) involving 53,688 active blood donors with extensive donation histories and
8	228,060 controls from biobank cohorts within the FinnGen project. Our results identified 2,973
9	genome-wide significant loci associated with repeated blood donation and impacting several health-
10	related endpoints. Importantly, significant variants related not only to blood groups but also
11	influenced the predisposition to somatic and mental diseases, suggesting that HDE is not solely tied
12	to blood donation eligibility criteria. In conclusion, in this work we show that HDE is partially
13	explained by genetic factors affecting various disease categories.
14	
1 5	
15	
16	
17	
10	
10	
19	
20	
21	
21	
22	
23	
24	
24	
25	
26	
27	Keywords: blood donor, biobank, healthy donor effect. GWAS. blood group. HLA

28 Introduction

Blood donors play an important role as an excellent healthy control cohort in genetics and
biomedical research due to their commitment and altruistic nature¹. Their voluntary and frequent
blood donations offer unique opportunities for longitudinal sampling. In addition, blood donors
exhibit positive attitudes toward the use of their samples and data in scientific research, if not
directly required in patient care^{2,3}.

34 However, blood donors are a highly selected population due to the health status criteria they must 35 meet to be eligible to donate blood. Along with a general survey of the donor's current state of 36 health, basic restrictions on blood donation suitability include serious illnesses such as severe 37 cardiovascular conditions, cancer and epilepsy⁴. Some conditions that restrict blood donation 38 suitability have strong well-known genetic background, such as the association of HLA genes in type 1 diabetes (T1D)⁵ or in certain autoimmune diseases^{6–8}. As a minimum hemoglobin level is required 39 40 for donation eligibility, genetic variants affecting iron and hemoglobin levels may also cause donor 41 selection. Due to these factors, blood donor selection results in a known phenomenon, healthy 42 donor effect, HDE, which can lead to detrimental effects in a research setting if not taken into 43 account⁹.

44 Comprehensive selection of different blood groups, and especially a sufficient amount of emergency blood type O RhD neg suitable for most recipients, are basic requirements in blood banks. Due to the 45 46 high need for emergency blood O RhD neg and strong immunogenicity of certain blood group antigens, such as ABO, Rh and Kell^{10–13}, donor recruitment is partially based on blood group 47 48 genotype and results in enrichment of certain blood group antigens in a blood donor pool. Well 49 known associations between ABO blood group antigens and cardiovascular conditions exist, more precisely between red cell antigen O and reduced thromboembolic diseases^{14,15}. Risk for bleeding 50 disorder, Von Willebrand disease, is known to be higher among individuals with red cell O antigen¹⁶. 51 52 Pregnancy-induced hypertension has been previously described to occur more in RhD positive

individuals¹⁵. Moreover, in certain medical conditions, such as in hemochromatosis, blood donation
may be beneficial, and donors with these conditions may be enriched in the blood donor
population¹⁷.

Enrichment of genetic variants with known disease associations or biological functions may result in
unpredicted effects in biomedical research. To reveal the genetic qualities of blood donors and to
understand the possible genetic selection leading to the HDE, we conducted a genome-wide
association study (GWAS) between the Finnish Red Cross Blood Service Biobank, and FinnGen (Figure
1). In addition, our aim was to discover genetic variants potentially contributing to blood transfusion
efficacy.

62 To our knowledge, no previous genome studies have focused on the possible selection bias caused 63 by blood group and health questionnaire-based requirement of blood donors. We found altogether 64 2,973 genome-wide significant associations. Genetic correlation analysis revealed strong negative 65 correlation between blood donorship and diseases such as mental disorders, pain disorders, 66 cardiovascular diseases, addiction disorders, autoimmune disorders, and Alzheimer's disease. HLA 67 association analysis confirmed the enrichment of hemochromatosis related HLA alleles and the 68 lower occurrence of autoimmune related HLA alleles in the blood donor population and indicated a 69 risk SNP tagging both hemochromatosis and autoimmune related HLA alleles. The genome-wide 70 significant variants associated with 112 plasma protein level alterations. The results of this study 71 demonstrate the genetic basis of the HDE, which is not limited to immediate blood donorship 72 inclusion criteria.



73

Figure 1 General workflow of the study. GWAS was performed on 53,688 cases (blood donors) and 228,060 controls. Genome wide significant GWAS results were fine-mapped and further used for several association analyses. Genetic correlation of 2470 phenotypes to blood donorship were calculated based on GWAS results. In addition, we imputed red cell antigens and tested their association to blood donorship. Previously imputed HLA alleles in FinnGen project were used to perform association analysis to blood donorship. Figure is created with BioRender.com

80

81

82 Results

- 83 Demographic information and differences in diagnoses between the two cohorts are described in
- 84 Table 1. In both sexes the blood donors were younger, taller and in males also heavier. More female
- 85 participants were seen in the blood donor cohort. A clear and significant difference between the two
- 86 cohorts was seen in both sexes in all the diagnose groups apart from 'XVI Certain conditions
- 87 originating in the perinatal period' where more incidents were found among blood donors in both

88 genders. FinnGen cohort consisted of donors in hospital biobanks but also donors in population

89 cohorts and in occupational health (Supplementary Table 1).

90

	Females		Ma	ales
	Blood donors	FinnGen	Blood donors	FinnGen
Median age at sampling, years (IQR)	44.47 (18.2-70.8)	62.7 (36.2-89.2)	50.26 (25.5-75.0)	70.46 (51.3-89.6)
Female sex, n (%)	32,460 (60.46)	120,279 (52.74)	21,228 (39.54)	107,781 (47.26)
Median weight, kg (IQR)	72 (54-90) ª	72 (51-93) ª	86 (68-104)	84 (64-104)
Median height, cm (IQR)	167 (159-175)	164 (156-172)	180 (171-189)	177 (168-186)
Median BMI (IQR)	25.83 (19.3-32.4)	26.64 (19.1-34.2)	26.58 (21.6-31.6)	26.88 (21.2-32.6)
FinnGen endpoint category ^b				
I Certain infectious and parasitic diseases (AB1)	7,466 (23)	47,901 (39.82)	5,565 (26.22)	48,487 (44.99)
II Neoplasms from cancer register (ICD-O-3)	968 (2.98)	34,299 (28.52)	791 (3.73)	38,891 (36.08)
II Neoplasms from hospital discharges (CD2)	6,960 (21.44)	67,026 (55.73)	2,804 (13.21)	52,708 (48.9)
III Blood and immune system (D3)	964 (2.97)	17,017 (14.15)	534 (2.52)	15,606 (14.48)
IV Endocrine, nutritional and metabolic (E4)	10,269 (31.64)	83,780 (69.65)	3,029 (14.27)	58,530 (54.3)
IX Circulatory system (I9)	6,276 (19.33)	69,429 (57.72)	4,587 (21.61)	78,876 (73.18)
V Mental and behavioural disorders (F5)	7,871 (24.25)	42,676 (35.48)	3,648 (17.18)	33,080 (30.69)
VI Nervous system (G6)	6,431 (19.81)	54,710 (45.49)	4,501 (21.2)	51,142 (47.45)
VII Eye and adnexa (H7)	8,088 (24.92)	58,567 (48.69)	4,660 (21.95)	47,174 (43.77)
VIII Ear and mastoid process (H8)	5,316 (16.38)	29,249 (24.32)	3,893 (18.34)	26,561 (24.64)
X Respiratory system (J10)	14,408 (44.39)	69,022 (57.38)	11,532 (54.32)	69,209 (64.21)
XI Digestive system (K11)	27,542 (84.85)	106,938 (88.91)	17,037 (80.26)	90,482 (83.95)
XII Skin and subcutaneous tissue (L12)	7,710 (23.75)	43,402 (36.08)	4,096 (19.3)	32,486 (30.14)
XIII Musculoskeletal and connective tissue (M13)	13,715 (42.25)	83,931 (69.78)	9,118 (42.95)	68,570 (63.62)
XIV Genitourinary system (N14)	17,334 (53.4)	91,665 (76.21)	4,463 (21.02)	49,729 (46.14)
XIX Injury, poisoning, external (ST19)	15,936 (49.09)	73,725 (61.29)	13,051 (61.48)	70,375 (65.29)
XV Pregnancy, childbirth and the puerperium (O15)	20,560 (63.34)	86,799 (72.16)	0 (0)	0 (0)
XVI Perinatal period (P16)	535 (1.65)	1,000 (0.83)	263 (1.24)	514 (0.48)
XVII Congenital malformations (Q17)	2,018 (6.22)	10,032 (8.34)	1,231 (5.8)	7,258 (6.73)
XVIII Abnormal clinical and laboratory findings (R18)	16,800 (51.76)	93,458 (77.7)	9,125 (42.99)	80,419 (74.61)
XX External causes of mortality (VWXY20)	13,025 (40.13)	64,874 (53.94)	10,741 (50.6)	62,034 (57.56)
XXI Contact with health services (Z21)	24,581 (75.73)	10,4068 (86.52)	10,544 (49.67)	72,915 (67.65)
XXII Codes for special purposes (U22)	1,417 (4.37)	5,906 (4.91)	595 (2.8)	4,310 (4)

^a Not significant

^b Shortened for clarity

91

92 Tak	ole 1 Demographic	information of the cohorts.	Age, sex, hei	ight, weight,	BMI and FinnGen
--------	-------------------	-----------------------------	---------------	---------------	-----------------

- 93 endpoint categories in blood donors and FinnGen cohort are shown. Apart from weight in females,
- 94 difference between the cohorts in each phenotype was statistically significant.

95

- 97 Genome-wide association analysis
- 98 Genome-wide association analysis revealed 2,973 significant (p < 5x10⁻⁸) genetic loci associated with
- 99 blood donorship. After fine-mapping, 5 coding (4 missense and 1 inframe deletion) and 36 non-
- 100 coding variants were detected (Figure 2A). In addition to these 41 variants, 5 non-coding lead

101 variants in the extended MHC region (Figure 2B and C) were included in the downstream analyses

102 (Table 2).

- 103 The strongest genome-wide associations were seen in variants related to blood group antigens:
- 104 rs55794721, p = 8.88x10⁻⁸⁹, in chromosome 1, rs687621, p = 5.70x10⁻⁸¹, in chromosome 9 in *ABO* and
- 105 rs8176058, p = 1.16x10⁻³¹, in chromosome 7 in *KEL* (Figure 1A, Table 2).
- 106 Despite of the adjustment of the GWAS for BMI, we observed significant GWAS variants known to
- 107 influence height, weight, and BMI. rs66781921, an inframe deletion variant in chr2, previously
- 108 shown to have a negative association to height, weight and body mass index¹⁸, was rarer in blood
- donors (beta = -1.97, p = 1.89×10^{-11}). Missense variant rs34811474, previously shown to be
- 110 negatively associated with body mass index¹⁸, was seen to be more frequent in blood donors (beta =

111 0.064, p = 1.21×10^{-12}). Variants rs10947114 (p = 2.88×10^{-09} , beta = 0.055), rs3130906 (p = 5.17×10^{-12}).

- 112 ¹¹, beta = 0.055) and rs4713637 (p = 1.39×10^{-08} , beta = -0.047), previously described to be
- associated with spondylopathies and celiac disease¹⁸, were negatively associated with blood
- donorship. A rare intron variant, rs528492111, in chromosome 3 previously shown to have a weak
- association to benign neoplasm of conjunctiva¹⁸, was more frequent in blood donors (beta = 1.87, p
- 116 = 4.09 x 10⁻¹⁰).
- All the fine-mapped and MHC lead variants in the are listed in Table 2.



119Figure 2 A) Manhattan plot of the genome-wide association study of blood donorship. B) Extended120MHC region of the chromosome 6 of the GWAS. C) Chromosome 6 association study adjusted for121type 1 diabetes, T1D. Red dot indicates fine-mapped variants in panel A and in panels B and C the122highest variant in each peak reaching the genome wide significance, <5 x 10⁻⁸. The name of the123nearest gene is shown for these variants if the p-value is $\leq 5x10^{-9}$. The horizontal line has been set to124 5×10^{-8} .

132

Genome wide association study						pQTL
rs ID	p-value	Beta	Effect	Target gene	Nearest	Target protein
rs66781921	1,89E-11	-1,973	inframe deletion	NCL	SNORD82	-
rs1135071	2,93E-13	-0,573	missense	HBB	HBB	AHSP
rs199598395	1,55E-25	-0,383	missense	RNF43	SUPT4H1	FTL, HAMP, FGF23
rs8176058	1,16E-31	-0,327	missense	KEL	KEL	KEL
rs191302298	3,89E-08	-0,292	intron	LINC01411	MSX2	-
rs10096658	1,35E-08	-0,277	intron	ZFPM2	LRP12	-
rs62113181	8,06E-09	-0,135	intron	KDM4B	KDM4B	-
rs75738358	4,89E-08	-0,080	intergenic	NA	MIR4801	-
rs12539059	5,68E-09	-0,071	downstream gene	COL26A1	LINC01007	KLK11
rs9272324	1,36E-16	-0,064	intron		HLA-DQA1	HERC5, METTL2B,
						MICB, HLA-DRA,
						C4B*
rs36035346	5,48E-09	-0,062	intron	CRTC1	CRTC1	-
rs60678519	1,06E-08	-0,055	downstream gene	1, AC079780	RPS2P32	GPNMB
rs10947114	2,88E-09	-0,055	intron		SFTA2	DDR1
rs3130906	5,17E-11	-0,055	intron		HCP5	MICA, CDSN, MICB
rs80319585	1,92E-08	-0,055	intron	KCNMA1	KCNMA1	-
rs7795945	1,28E-09	-0,049	intron	PCLO	PCLO	-
rs34483988	1,65E-08	-0,049	intron	FAM171B	FAM171B	-
rs6775319	2,17E-09	-0,048	intron	SATB1-AS1	SATB1	-
rs7907026	4,63E-10	-0,048	intergenic	NA	SORCS3	-
rs3806234	5,16E-09	-0,047	upstream gene	SNAPIN	SNAPIN	-
rs4713637	1,39E-08	-0,047	intergenic		LINC00336	-
rs62083414	5,35E-09	-0,046	intron	DCC	DCC	-
rs207350	3,03E-08	-0,045	intergenic	NA	LCORL	-
rs594398	1,18E-08	-0,044	intron	SUMO2P17	ATP5G1	-
rs10880819	2,64E-08	0,043	downstream gene	RF00019	ALG10B	-
rs35440643	4,54E-08	0,044	intron	ZNF638	ZNF638	-
rs10166897	1,57E-08	0,044	intron	MAPRE3	MAPRE3	CGREF1
rs113236240	6,53E-09	0,045	intron	PPCDC	PPCDC	MPI, PPCDC
rs55763604	2,84E-08	0,049	intron	BNC2	BNC2	-
rs55732343	2,31E-10	0,049	regulatory region	NA	SLC9A1	-
rs9968910	1,12E-09	0,050	intergenic	NA	HIST1H1C	-
rs5821444	7,98E-09	0,051	3 prime UTR	C17orf58	C17orf58	-
rs6498415	5,47E-10	0,053	intron	1, U91319	SHISA9	-
rs12444334	1,51E-09	0,053	intron	GAS8	C16orf3	CDH15
rs11675100	3,88E-09	0,054	intron	1, AC007100	MIR4432	-
rs9367942	3,81E-08	0,055	intron	STMND1	STMND1	-
rs61937595	1,25E-08	0,062	intron	R3HDM2	R3HDM2	INHBC
rs34811474	1,21E-12	0,064	missense	ANAPC4	ANAPC4	-
rs1500956	5,14E-10	0,075	intron	PDE4B	PDE4B	-
rs77448558	1,28E-08	0,078	intergenic	NA	GRIK2	-
rs10268629	1,71E-09	0,078	intergenic	NA	TAC1	-
rs75350584	1,58E-08	0,094	intron	DLEU1	ST13P4	-
rs687621	5,70E-81	0,147	intron	ABO	ABO	63 different
rs55794721	8,88E-89	0,157	upstream gene	SYF2	SYF2	ICAM4
rs118101548	1,90E-08	0,299	intron	POLD1	POLD1	-
rs528492111	4,09E-10	1,875	intron	WDR6	WDR6	-

133

134	Table 2. Fine-mapped and MHC lead variants. Significance, effect size, the most serious effect and	
-----	--	--

nearest gene for each variant is shown. If the variant was associated with altering protein expression

136 levels, the target proteins are shown.

137

139 Genetic correlation

Altogether 593 phenotypes were negatively correlated with blood donorship (FDR < 0.05,
Supplementary file 2). Height was the only phenotype showing weak positive correlation with blood
donorship, rg = 0.07 (Figure 3A) despite the GWAS having been adjusted for BMI. Phenotypes
associated with some of the individual variants detected by the GWAS with a relatively strong effect
size did not show strong correlation with blood donorship. In turn, some phenotypes associated with
individual variants with small effect size in GWAS were relatively strongly correlated to blood
donorship (Figure 3B).

- Blood donorship was negatively correlated with $r_g < -0.5$ to 30 phenotypes (Supplementary file 2).
- 148 The strongest negative correlation (r_g < -0.6) in blood donors was seen with Anemias (r_g = -0.66, FDR

149 = 2.81×10^{-112}), 'Other reaction to severe stress and adjustment disorders' (r_g = -0.64, FDR = 3.36×10^{-112})

150 10^{-40}) and 'Other disorders of teeth and supporting structures' ($r_g = -0.62$, FDR = 2.74x10⁻⁰³).

151 Furthermore, negative correlation was observed in phenotypes such as autoimmune diseases (r_g = -

152 0.33, FDR = 1.87×10^{-52}), cardiovascular diseases (excluding rheumatic etc) ($r_g = -0.42$, FDR = 3.79×10^{-52})

153 10^{-64}) and bleeding disorders (r_g = -0.39, largest FDR = 7.10 x 10^{-11}) (Figure 3C). In addition, negative

154 correlation to blood donorship was observed in phenotypes such as addiction disorders (rg = -0.33,

largest FDR = 7.09 x 10^{-04}), pain disorders (r_g = -0.45, largest FDR = 1.41 x 10^{-10}) and Alzheimer's

disease (r_g = -0.24, FDR = 0.03) which are not directly restricted by blood donation eligibility criteria,

but which undeniably effect on donation suitability or donor's knowledge on their current state of

158 health. Another example of phenotypes not directly restricted by blood donation eligibility but with

159 relatively strong negative correlation towards blood donorship are infectious phenotypes, such as

acute bronchitis ($r_g = -0.58$, FDR = 1.76 x 10⁻¹⁶) and 'other or unspecified bacterial infection' ($r_g = -$

161 0.50, FDR = 1.83×10^{-09}) (Figure 3A, Supplementary file 2).



162

Figure 3. Genetic correlation of blood donorship to 594 phenotypes. A) Genetic correlation of 40 163 phenotypes representing the strongest negative and strongest positive correlation to blood 164 165 donorship. B) For each of the 46 variants and their most significantly associated FinnGen phenotypes 166 the effect size of the variant and the genetic correlation of the phenotype to blood donorship is shown. The phenotype is labeled when the absolute value of the effect size is higher than 0.25. 167 The vertical bars indicate the standard error of the genetic correlation estimate. C) Genetic 168 169 correlation matrix of selected phenotypes. Pain disorders, mental disorders, bleeding disorders and addiction disorders have been grouped from several phenotypes belonging to same phenotype 170 category and average genetic correlation is shown. This results in some of the diagonal elements 171 172 being less than one. 173

175 Red cell antigen related associations

To understand whether blood donor selection leads to enrichment of blood groups in the blood
donors, we evaluated the association of imputed red cell antigens with blood donorship using a
logistic regression model. The model revealed a strong negative association for blood group antigens
Kell, RhD, and AB and a positive association for blood group antigen O (Figure 4A). Results of the
GWAS covariates and red cell antigens are available in Supplementary file 2.
We further analyzed the blood group related significant GWAS variants in chromosomes 1, 7 and 9

182 with linear regression models. Lead variant in chromosome 1, rs55794721, was associated with the

183 Rh blood group system (previously shown to be associated with height¹⁸). Rh antigens E, C and D

184 were negatively associated with rs55794721, whereas e and c antigens of the most common Rh

negative haplotype in the Caucasoid population, dce¹¹, were positively associated with rs55794721

186 (Figure 4B). 91% of individuals that were positive for Rh c and e alleles and had no Rh D, C or E

alleles, were homozygotes (dosage value > 1.5) for rs55794721. rs55794721 is in LD^{19} (R² = 0.39) with

variant rs586178 tagging certain RhCE blood group alleles²⁰. Lead variant in chromosome 7,

rs8176058, a known tag SNP for Kell blood group antigen²⁰ was positively associated with K antigen

190 (Figure 4C). Lead variant in chromosome 9, rs687621¹⁹, is in strong LD, R² = 1 with blood group O

tagging SNP rs687289²¹. We could also see a strong positive association of rs687621 with blood

192 group O, a positive association with blood group antigen B and a negative association with blood

193 group antigen AB (Figure 4D).



194

195 Figure 4 Association of red blood cell antigens with blood donorship, rs55794721, rs8176058 and 196 rs687621. Red cell antigens K, Dob, D and AB were negatively, and red cell antigen O positively 197 associated to blood donorship. Red cell antigens c and e belonging to the most common Rh-negative 198 haplotype Rh dce were positively associated to rs55794721, whereas red cell antigens D, C and E 199 were negatively associated with rs55794721. Red cell antigens Cw and Cx were negatively associated 200 with rs55794721. Red cell antigen K was positively associated with rs8176058. Red cell antigens O 201 and B were positively associated and red cell antigen AB negatively associated with rs687621 in ABO 202 gene.

203

204

206 Hemoglobin related associations

207 As hemoglobin value within a specified interval is a required for blood donation eligibility, we 208 investigated whether some of the genome-wide significant variants were associated with 209 hemoglobin. Hemoglobin-related associations were seen in chromosomes 6, 9, 11 and 17 in variants 210 rs9968910, rs3130906, rs687621, rs1135071 and rs199598395, respectively (Supplementary Figure 211 1). We observed a negative association between rs199598395 in RNF43 gene in chromosome 17 and 212 blood donorship. rs199598395 has been previously shown to be Finnish enriched and associated with iron deficiency anemia²² and to have an effect on blood donation eligibility²³. Negative 213 214 association in blood donorship was also seen with rs1135071 in chromosome 11, in a known Finnish 215 enriched Hb variant, Hb Tacoma²⁴, in HBB gene. Linear regression analysis of blood service 216 operational finger-prick Hb measurements showed a decreasing effect of rs199598395, rs1135071 217 and rs3130906 to hemoglobin level -2.99 g/L (p = 6.43 x 10⁻³⁰, 95% Cl [-3.49, -2.5]), -6.46 g/L (p = 6.66 218 x 10⁻²⁸, 95% CI [-7.57, -5.35]) and -0.22 g/L (p = 0.002, 95% CI [-0.32, -0.11]) respectively, and moderate increasing effect of rs9968910 and rs687621, 0.52 g/L (p = 4.03 x 10⁻²², 95% CI [0.42-0.62]) 219 and to 0.25 g/L ($p = 1.72 \times 10^{-05}$, 95% Cl [0.15-0.35]), respectively (Supplementary file 2). In summary, 220 221 all the alleles of these five variants that had an increasing effect on hemoglobin, were more frequent 222 in blood donors (Table 2). 223 We detected a higher allele frequency, 0.69, of rs9968910, previously shown to be associated with

diseases of iron metabolism¹⁸, among patients with clinical hereditary hemochromatosis (ICD10 code E83.1) in FinnGen (N=477) compared to population level in Finland, 0.33^{25} . rs9968910 is in weak LD with known HFE mutations causing hemochromatosis: rs1799945 (H63D, R² = 0.18) and rs1800562 (C282Y, R² = 0.1)¹⁹.

228

229 Association of the HLA alleles

230 Because of the known strong role of the HLA region in immunology and the predisposing risk of 231 certain HLA alleles in autoimmunity 5-8,26, we performed an association study with imputed HLA alleles for blood donor endpoint. We could see a strong association ($p = 1.36 \times 10^{-16}$) with rs9272324 232 233 in chromosome 6 in HLA-DQA1 gene in the genome-wide association study of blood donorship 234 (Figure 1B). However, after adjusting with T1D (ICD10 E10 and ICD9 250), no significant association 235 in HLA-DQA1 gene was seen (Figure 1C). HLA association analysis for the blood donor phenotype 236 (Figure 5, upper panel) revealed negative association with HLA-alleles of the well-known T1D risk 237 genotypes HLA-DQ2 and DQ8 which are in linkage with HLA haplotypes DRB1*03:01-DRB3*01:01-DQA1*05:01-HLADQB1*02:01 and DRB1*04:01- DRB4*01:03- DQA1*03:01- DQB1*03:02, 238 239 respectively. The HLA alleles in linkage with HLA-DQ8 were negatively associated with blood donorship: DRB1*04:01 (beta = -0.12, p = 2.2 x 10⁻¹¹), DRB4*01:03 (beta = -0.06, p = 2.75 x 10⁻⁸), 240 DQA1*03:01 (beta = - 0.09, p = 1.16 x 10⁻⁸) and DQB1*03:02 (beta = -0.09, p = 9.99 x 10⁻⁹). HLA-241 242 alleles previously shown to be associated with HFE C282Y allele in Finland¹⁷ B*07:02 (beta = 0.07, p = $5.45e-10^{5}$), *DRB1*15:01* (beta = 0.06, p = 5.45×10^{-5}), *DQA1*01:02* (beta = 0.05, p = 5.45×-10^{-5}) and 243 244 DQB1*06:02 (beta = 0.06, p = 9.24 x -10⁻⁵) were positively associated with blood donorship. HLA-DRB5*01:01 (beta = 0.06, p = 5.45 x 10⁻⁵) and *HLA-DPB1*05:01* (beta = 0.1, p = 0.04) were positively 245 associated with blood donorship. Furthermore, HLA-B*27:05 (beta = -0.07, p = 1.96×10^{-3}), a well-246 known ankylosing spondylitis risk allele²⁶, was negatively associated with blood donorship. 247 248 Adjustment with chr6 lead variant, rs9272324 (Figure 5, middle panel), decreased the effect sizes 249 and increased p-values of the above-mentioned HLA alleles in linkage with HLA-DQ8 and HLA-250 B*27:05 and increased the p-values of the above mentioned HFE C282Y related HLA-alleles above 251 the significance level (Supplementary file 2). Furthermore, when adjusted with the lead HLA-allele, *DRB1*04:01* (Figure 5, lower panel), *HLA-B*27:05* (beta = -0.08, p = 2.84×10^{-04}) and *HLA-C*02:02* 252 (beta = -0.06, p = 2.95 x 10^{-02}) in LD (r^2 = 0.3) with *HLA-B*27:05*, HLA-alleles in linkage with the T1D 253 risk genotype HLA-DQ2; DRB1*03:01 (beta = -0.05, p = 4.31 x 10⁻⁰³), DQA1*05:01 (beta = -0.06, p = 254 255 2.45 x 10⁻⁰³), DQB1*02:01 (beta = -0.06, p = 4.31×10^{-03}) and HLA-B*08:01 (beta = -0.05, p = 4.2×10^{-10}

- ⁰²), a known *HLA-B* allele in in linkage with *HLA-DQ2* in Finland, were negatively associated with
- 257 blood donorship (Figure 4, lower panel). In *HLA-DRB1*04:01* adjusted analysis, HFE C282Y related
- 258 HLA alleles B*07:02, DRB1*15:01, DQA1*01:02 and DQB1*06:02 were positively associated with
- 259 blood donorship, but with lower p-values than in HLA-association analysis without any adjustment

260 (Supplementary file 2).



261

262

263 Figure 5. Conditional *HLA* association analysis. Upper panel: *HLA* association analysis for blood

- 264 donorship. Middle panel: *HLA* association analysis for blood donorship adjusted with rs9272324.
- Lower panel: *HLA* association analysis for blood donorship adjusted with *HLA-DRB1**04:01.
- 266 Covariates used in all the analysis: age, sex, BMI, PC1-10, birth region and FinnGen genotyping array
- version. Dotted horizontal line corresponds to the highest p-value that still fits the FDR limit of 0.05.

269

270

271 Variants altering protein expression levels

272	To investigate the function of the lead GWAS variants more closely, we employed protein
273	quantitative trait loci (pQTL) and functional enrichment analyses. Of the 41 fine-mapped and five
274	MHC region variants (Table 2), 14 were found to be significantly associated (FDR <0.05) with 81
275	unique plasma protein expression levels. Most of the associations, comprising 63 unique proteins,
276	were found with rs687621 located in the ABO gene. These included genes that encode for proteins
277	fundamental to the histo-blood group ABO formation, such as ABO antigens, and FUT1, the H-
278	antigen. The latter is converted by glycosyltransferase expressed by individuals with A, B or AB into
279	antigen A or B while individuals with the O blood group antigen lack this activity ²⁷ . Decreasing effects
280	on expression were seen for e.g. FUT1, VWF, F8 and CLEC4M, and increasing effects for ALPI and
281	SELE. Importantly, rs55794721 exerted a decreasing effect on ICAM4, a gene encoding for LW
282	glycoprotein present in the RhD protein complex (Figure 6). In addition, two variants were
283	associated with protein expression levels of genes putatively associated with carcinogenesis (Figure
284	6). rs12539059 regulates protein levels of <i>KLK11</i> , a kallikrein suspected to play a role in
285	carcinogenesis in human tissues ²⁸ . Another putatively cancer-related ²⁷ protein association was seen
286	for rs60678519 and GPNMB. Overexpression of GPNMB has been shown to lead into
287	immunosuppression within tumor immune microenvironment and further into poorer prognosis in
288	variety of cancers ²⁹ .
289	The STRING ³⁰ functional enrichment analysis tool identified several functional processes (PPI
290	enrichment p-value < 1 x 10^{-16}) among the 81 proteins. Gene Ontology (GO) revealed the enrichment
291	of cell adhesion molecules in biological processes and molecular functions. These molecules were
292	further refined to ICAM, C-type lectin and immunoglobulins in protein domains. Other functional

categories were blood groups, hemoglobin and iron metabolism, immunology, and cell-cell adhesion(Supplementary file 3).

- 295 We detected three associations with protein expression level alteration that weren't involved with
- any of the enriched biological or cellular processes (Supplementary file 3). rs113236240 showed an
- 297 increasing effect (beta = 0.36) on PPCDC, encoding for a protein needed in coentzyme A
- biosynthesis²⁷. rs687621 showed a decreasing effect (beta = -0.4) on *GOLM2*, a proto-oncogene
- 299 whose overexpression associates with proto-oncogene HER2/neu, found in human breast and
- 300 ovarian cancers²⁷. rs1135071 showed a strong increasing effect (beta 2.57) on AHSP (Figure 6), which
- 301 encodes for chaperone protein binding free alpha-globin and therefore having a stabilizing effect in

302 hemoglobin assembly²⁷.



303

Figure 6 Association of the variants to protein expression level alteration. Six variants with
 association to protein level alteration in pQTL analysis are shown in the figure. The lead variant in
 ABO gene rs687621, was found to be associated to 63 unique protein level alterations. Lead variant
 in MHC region in unadjusted GWAS, rs9272324, showed association mainly to immunity related
 protein level alteration. Variants with decreasing effect on hemoglobin level (Supplementary file 2)

rs199598395 and rs1135071 showed association to iron metabolism genes and hemoglobin related
 gene, respectively. rs6067859 and rs12539059 showed increasing effect on expression of putative
 cancer-related genes. All the variants effecting on protein levels can be found in Table 2 and in more
 detail in Supplementary file 3.

313

314 Putative bias caused by red cell antigen enrichment in research setting

315 Protective association of red cell antigen O to venous thromboembolism (VTE) has been shown

previously by multiple studies^{14–16}. To investigate the putative bias an ABO enrichment could cause

to VTE association study, we conducted an association analysis with VTE as an endpoint in

318 chromosome 9 (Supplementary Figure 2A) by adjusting for imputed ABO antigens (Supplementary

Figure 2). Our results showed that after the adjustment, the p-value of the lead variant failed to

reach the genome-wide significance level 5 x 10^{-8} (rs582118 unadjusted p = 3.28×10^{-115} , ABO

adjusted $p = 1.16 \times 10^{-6}$) but the signal was not completely removed as some genome-wide

322 significant variants still remained (Supplementary Figure 2A-B). The adjustment not only removed

323 associations of some SNPs but also made visible other variants not detected in the basic analysis

324 (Supplementary Figure 2C).

We could see a strong association of rs55794721 (beta = 0.16, $p = 8.88 \times 10^{-89}$) to blood donorship

and furthermore we showed the association of this variant to RhD negative haplotype, Rh dce

327 (Figure 4). rs55794721 is previously shown to be associated with height¹⁸. The blood donors are

taller than the control population (Table 1) and due to the strong immunogenity of RhD blood group

329 system¹¹, the Rh dce tagging rs55794721 is enriched in blood donor population (Table 2). To

330 understand the possible bias the RhD negative enrichment could cause, we conducted an association

331 study for height and adjusted the primary analysis with cohort information. Our results show that

332 RhD dce enrichment can cause bias in research setting. Prior the adjustment, rs55794721 was

- statistically significant ($p = 1.74 \times 10^{-13}$) but after the adjustment failed to reach reduced the
- genome-wide significance level 5 x 10^{-8} (after adjustment p = 6.86 x 10^{-7}). Furthermore, the effect

- size of the variant varied depending on the adjustment (rs55794721 unadjusted beta = 0.14,
- adjusted beta = 0.09) (Supplementary Figure 3).
- 337
- 338
- 339 Discussion
- 340 In the present study we conducted a genome-wide comparison between blood donor biobank
- 341 donors with relatively long and active blood donation history¹⁷ and FinnGen. The FinnGen control
- 342 population included biobank participants from hospital biobanks as well as from population cohorts
- 343 and patients at occupational health clinics. As the latter two cohorts comprise largely healthy
- individuals, and the disease-specific legacy cohorts were excluded from the analysis, the study
- 345 controls are likely representative of the general Finnish population.
- Negative genetic correlation towards blood donorship was observed with several phenotypes, which could be a consequence of HDE. Strong negative correlation to anaemias in blood donors could be a result of blood donation eligibility but just as well certain autoimmune diseases, such as Crohn's disease, which may cause anaemia through secondary blood loss.

350 The observed protection of blood donors from certain diseases can be directly explained by donor 351 eligibility criteria that selects healthy individuals. For example, blood donors lack viral hepatitis due 352 to the exclusion of infected individuals. Surprisingly, our results reveal that blood donors not only 353 exhibit a protective genetic profile against viral hepatitis, but also a broader negative genetic 354 correlation extending beyond viral hepatitis to infectious diseases in general, even though these are 355 not explicitly targeted by donor eligibility criteria. This kind of negative genetic correlation also 356 manifests in various mental illnesses and Alzheimer's disease. While pleiotropic effects may explain 357 the phenomenon, our analyses indicate that genetic correlation with the phenotype targeted by the 358 eligibility criteria is not consistently strong. Further detailed investigations are needed to fully

understand pleiotropy in blood donor selection and to explore the potential benefits of an activeblood donor population for genetic and biomedical research.

361 Expectedly, genetic variants in the MHC region played strong role in several genetic associations as 362 well as in genetic correlation. HLA alleles with known autoimmune associations occurred with lower 363 frequency in the blood donor population than in the control population, whereas hemochromatosis 364 related HLA alleles were more frequent among the blood donors. We have previously shown the 365 enrichment of HFE C282Y homozygotes and certain HLA haplotype within these donors in the Blood 366 Service Biobank¹⁷. These findings were repeated in the present study with new variants, rs9968910, 367 more frequent among patients with clinical hemochromatosis diagnosis (ICD10: E83.1) and 368 rs9272324 tagging several autoimmune related HLA haplotypes, including hemochromatosis related 369 HLA haplotype. However, we could not see the ancestral hemochromatosis marker HLA-A*03:01^{31,32} 370 in the HLA-association analysis. HLA-DPB1*05:01 hasn't been previously shown to be associated with 371 the HLA-A*03:01-C*07:02-B*07:02-DRB1*15:01-DQA1*01:02-DQB1*06:02 haplotype but instead has been shown to be enriched in with HLA-A*02:01-C*07:02-B*07:02-DRB1*15:01-DQA1*01:02-372 373 DQB1*06:02³³. However, our unpublished data shows that HLA-A*03:01-C*07:02-B*07:02-374 DRB1*15:01-DQA1*01:02-DQB1*06:02-DPB1*05:01 haplotype occurs in the Blood Service Biobank 375 with a frequency of 0.00011. Taken the enrichment of C282Y homozygotes in the Blood Service 376 Biobank and the positive association of these HLA alleles with blood donorship in this study into 377 consideration, it could be possible that this haplotype is associated with clinical hemochromatosis. 378 However, more studies are needed to confirm the HLA haplotype among donors with clinical 379 hemochromatosis. 380 In addition to tagging certain autoimmune related haplotypes, rs9272324 was shown to enhance the 381 protein levels of *HLA-DRA* encoding the nonpolymorphic *DR* alpha-chain³⁴ essential for the stabile

382 expression of DR molecules on cell surface. Taken this and the known autoimmune associations of

383 HLA-DRB1*15:01 into consideration, it could be possible that rs9272324 plays a role in the known

immunological abnormalities often met in patients with clinical hemochromatosis. Furthermore, the
significantly higher frequency of rs9968910 and rs9272324 among individuals with clinical
hemochromatosis diagnosis, could shed a light in the long discussed low penetrance of the well
described *HFE* variants *C282Y* and *H63D* in clinical hemochromatosis.

The strong immunogenicity of certain blood group antigens^{10–13} as well as the constant need of the 388 389 emergency blood, O RhD neg, causes enrichment of these red cell antigens into the blood donor 390 population as demonstrated in the present study. Multiple studies have shown the relationship 391 between ABO blood group and cardiovascular conditions and more precisely the decreased risk of blood group O to thromboembolic end points^{15,35}. In research setting where blood donors are used 392 393 as a healthy control population, confounding factors as the blood group O enrichment should be 394 taken into consideration as shown in this study by VTE association analysis (Supplementary Figure 2). 395 Furthermore, the blood group antigen related variants rs55794721 allele A and rs687621 allele A 396 decreased the expression level of genes known to have a role in the function or structure of the 397 cognate blood group molecule, such as RhD accessory protein ICAM4, a Landsteiner-Wiener 398 glycoprotein¹¹, and FUT1, fucosyltransferase needed in the synthesis of red cell antigens A and B^{27,36}. 399 rs687621 alone altered expression levels of 63 genes, whose products are involved in various of 400 biological pathways (Supplementary file 3). Due to the blood group O enrichment in the blood donor 401 pool, these included e.g., decreasing effect on proteins with a role in hemostasis and thrombosis 402 such as VWF and F8. An increasing effect of protein levels of rs687621 allele A was seen with ALPI 403 and SELE, the former having a role in the defense system of gut mucosal and is thought to prevent 404 bacterial translocation and the latter been speculated to have role in atherosclerosis. Both of these 405 immunity and cardiovascular related biological functions are well-known roles of ABO blood group antigens^{14,15,36,37}. Furthermore, another red cell antigen related finding in this work was the variant 406 407 rs55794721, which was shown to tag the most frequent RhD negative haplotype in the European 408 ancestry, Rh dce.

409 In addition to hemochromatosis, the results of the present study highlight genetic factors with 410 possible effect on recipient matching or donation activity. We show a lower expression level of AHSP 411 protein in blood donors due to the lower occurrence of rs1135071 allele A, which was also shown to 412 decrease the hemoglobin level in this work. Consequently, blood donors had higher hemoglobin 413 levels. AHSP plays a role in hemoglobin assembly by stabilizing the α Hb subunits and preventing the 414 self-aggregation of the excess α Hb subunits prior the formation of HbA1 subunit³⁸. To our 415 understanding, no earlier studies indicate the increasing effect of Hb Tacoma variant rs1135071 on 416 AHSP levels. Taken the speculated role of AHSP as a genetic modifier in β thalassemia^{38,39} and the described normal clinical phenotype of *Hb Tacoma* heterozygotes in account⁴⁰, rs1135071 could be 417 418 of further interest in β thalassemia related research. Furthermore, regarding the donor health, it 419 may be useful to analyze whether blood donation is a harmless event for *Hb Tacoma* heterozygotes 420 or whether the blood products are suitable for recipients with e.g. sickle cell disease⁴¹. The known 421 association of rs199598395 with iron deficiency¹⁸, its effect on blood donation eligibility²³ and the 422 decreasing effect on hemoglobin level demonstrated in this study support the need for evaluating its 423 role in blood donation eligibility or interval in more detail.

424 In biomedical research, active blood donors offer valuable opportunities due to their positive 425 attitude toward research, availability for longitudinal sampling and unique genetic makeup. 426 However, when using blood donors exclusively as a control group, critical evaluation and 427 interpretation of results are essential. For instance, our VTE and height association analysis 428 highlights the need to consider possible blood group enrichment and its impact on disease risk to 429 adjust for cohort information to minimize biases. Moreover, genome-wide association studies in 430 FinnGen have been conducted without adjustment for the cohort information. Hence, the possibility 431 of HDE or blood group enrichment caused biases in the FinnGen results and therefore also in the 432 phenotype associations of this study, cannot be completely excluded for all the variants as was 433 shown with our height association study. In addition, Blood Service Biobank is one of the cohorts used for FinnGen association studies^{18,22}, which results are utilized on this study. Although blood 434

donors represent minority in FinnGen project, the putative accumulating impact on the effect sizesand p-values of this study, cannot be completely excluded.

437 In this study we present, to our knowledge for the first time, the genetic underpinnings of HDE and 438 blood group-based selection in active blood donors. Our findings highlight the unique genetic 439 makeup of this donor population and its impact on health and blood donation suitability. The results 440 demonstrate the role of genetics in maintaining good health status and active blood donation career that is also connected to a better mental health at the genetic level. Furthermore, research using 441 442 blood donors as a control group should account for this distinct genetic structure, even after 443 donation ceases. Additionally, the enrichment of specific blood group antigens among blood donors 444 warrants consideration in research. Further investigations are necessary to fully elucidate the 445 implications of these discoveries, but they underscore the genetic structure behind HDE and the 446 potential of active blood donor cohorts for advancing biomedical genetic research.

447

448 Material and Methods

449 Ethics statement

450 Study subjects in FinnGen provided informed consent for biobank research, based on the Finnish 451 Biobank Act. Alternatively, separate research cohorts, collected prior the Finnish Biobank Act came 452 into effect (in September 2013) and start of FinnGen (August 2017), were collected based on studyspecific consents and later transferred to the Finnish biobanks after approval by Fimea (Finnish 453 454 Medicines Agency), the National Supervisory Authority for Welfare and Health. Recruitment 455 protocols followed the biobank protocols approved by Fimea. The Coordinating Ethics Committee of 456 the Hospital District of Helsinki and Uusimaa (HUS) statement number for the FinnGen study is Nr 457 HUS/990/2017. Full list of permits numbers are listed in Supplementary information.

All the sample donors had given a written biobank consent. The use of the data in the present study
is in accordance with the biobank consent and meets the requirements of the Finnish Biobank Act
688/2012. A formal biobank decision 004-2022 for the research project has been granted by the
Finnish Red Cross Blood Service Biobank. The use of the FinnGen data has been accepted with
FinnGen proposal F_2022_086.

463

464 Data acquisition

465 Genome data used in the present study originated from samples that were genotyped in the 466 FinnGen project with the FinnGen ThermoFisher Axiom custom array v1 or v2 and genome 467 imputation version R12. Genotyping, quality control, and genome imputation protocols are described in detail in FinnGen Gitbook⁴². In short, genotype calling was performed with GenCall or 468 469 zCall algorithm for Illumina and AxiomGT1 algorithm for Affymetrix arrays. Prior the imputation, 470 genotyped samples were pre-phased with Eagle 2.3.5 with the default parameters, except the 471 number of conditioning haplotypes was set to 20,000. Genotype imputation was performed using 472 the population-specific imputation reference panel SISu v4.2 with Beagle 4.1 (version 27Jan18.7e1). 473 In addition to genome data, the following electronic health registry data and supplementing data 474 were utilized: ICD (ICD9 and 10) code for type 1 diabetes, occurrence of venous thromboembolism, 475 age, BMI, sex, region of birth and genetic principal components (PC) 1-10. Blood donation data 476 contained blood donation history and hemoglobin value measured at the point of each blood 477 donation event and was used when applicable. Donors with three or less donation events were 478 filtered from the hemoglobin analyses. Blood donation data was available from 44,675 donors. 479 Due to the known selection of healthy individuals as blood donors, legacy samples⁴², highly enriched 480 in certain common diseases, were filtered out from the study cohort to minimize possible bias in 481 downstream analyses. Individuals under 18 years of age were removed as 18 is the age limit of blood

482 donation. In addition, individuals born in regions in Finland that were ceded to Soviet Union were 483 filtered out due to age structure of the region and the maximum blood donation age of 70 years. As 484 BMI might influence donor eligibility, individuals lacking BMI information were filtered out. After filtering, total number of FinnGen genome data used in this study was 53,688 cases (blood donors) 485 486 and 228,060 controls (other FinnGen participants). 487 488 Methods 489 Statistical analyses If not stated otherwise, all statistical analyses were performed in R⁴³ version 4.3 or 4.4, with 490 RStudio⁴⁴. The genome-wide significance p-value threshold $p < 5 \times 10^{-8}$ was used in GWAS. In all 491 other analyses p-values were adjusted with the Benjamini–Yekutieli procedure⁴⁵, and significance 492 493 threshold of 0.05 was used. All the phenotypes described here, have been previously studied and 494 described in FinnGen in DF12 dataset. At the present, only DF10 data set is publicly available¹⁸. 495 496 Association analysis and fine-mapping 497 Genome-wide association study, GWAS, with an additive genetic model, was performed in FinnGen pipeline with Regenie^{46,47} v2.2.4 with blood donor status as a binary endpoint. Sex, age, BMI, PC1-10, 498 499 birth region, and FinnGen genotyping array version were used as covariates in the GWAS. To 500 discover associations independent of type 1 diabetes (T1D) in chromosome 6, the FinnGen T1D endpoint ²² was used as an additional covariate in the chromosome 6 association analysis. 501 502 Fine-mapping for the genome wide significant signals ($p < 5 \times 10^{-8}$) of the association study was performed in FinnGen pipeline⁴⁷ with SuSiE⁴⁸ excluding MHC region (GRCh38, chr6:25-34 Mb)^{22,42}. 503 504 For each fine-mapped locus we accepted the credible set as an independent hit if the strongest

primary p-value was $p < 5 \times 10^{-8}$. In case of multiple credible sets within a single locus, to accept the

secondary hit, we required genome-wide significance and log₁₀(Bayes factor) > 2. As the MHC region
is excluded from the fine-mapping pipeline due to its strong LD, the lead variants from the T1D
adjusted association analysis, rs9968910, rs10947114, rs3130906 and rs4713637, were selected for
the downstream analysis. Moreover, the lead variant in the MHC region in GWAS, rs9272324, was
included in the further analyses due to its strong association in autoimmunity¹⁸ and the
hypothesized lower association with autoimmunity among blood donors.

512 Association analysis for all the covariates used in GWAS and the imputed blood groups to the blood 513 donor end point was performed with logistic regression in R. We further analyzed the association of 514 all the covariates used in GWAS and imputed blood group antigens to the lead variants in dosage 515 form in chromosomes 1 (rs55794721), 7 (rs8176058) and 9 (rs687621) by using linear regression. 516 Association testing of each classical HLA allele HLA-A, -B, -C, -DRB1, -DQA1, -DQB1, DPB1 and HLA-517 DRB3-5 for the blood donor endpoint was performed using Regenie v3.0.1. First, a genotype data set for fitting Regenie null models was formed with Plink2 v2.00a4LM using FinnGen DF12 HapMap3 518 519 variants as a basis and randomly thinning the variants to 500 000 with further filtering for minor

allele frequency at least 0.1, Hardy-Weinberg equilibrium greater than p-value 1e-15 and minimum
allele count at least 100. Second, the Regenie null models were fitted on the filtered genotype data
and used in the association step to take consanguinity into account. To dissect the HLA signal
further, two additional association tests were performed: i) conditioning for GWAS chromosome 6
lead variant rs9272324 allele dosage and ii) conditioning for the HLA allele dosage with the strongest
association, *HLA-DRB1*04:01*, in the primary HLA association analysis.

To understand the putative bias caused by red cell antigen, ABO, enrichment in the blood donor
pool, we conducted an association study in chromosome 9 in FinnGen pipeline with Regenie^{46,47}
v2.2.4 with FinnGen venous thromboembolism²² as a binary endpoint. Sex, age, PC1-10, FinnGen
genotyping array version, and FinnGen batch information were used as covariates. In the primary
analysis there were 19,957 cases and 344,672 controls. The primary analysis was conditioned with

531	imputed ABO red cell antigens. After filtering out 20 individuals based on low posterior probability of
532	the imputed ABO antigens, 19,956 cases and 344,653 controls remained in the conditional analysis.
533	To further understand putative bias in FinnGen association results, we conducted an association
534	study in chromosome 1 in FinnGen pipeline with Regenie ^{46,47} v2.2.4 with FinnGen height ²² as a non-
535	binary endpoint. Sex, age, PC1-10, FinnGen genotyping array version, and FinnGen batch information
536	were used as covariates. The study had 364,629 cases. The primary analysis was conditioned with
537	cohort information, to minimize the possible bias of RhD dce enriched haplotype in blood donors.
538	
539	Genetic correlation
540	All pair-wise genetic correlations between blood donorship, hemoglobin and all the 2470
541	phenotypes previously studied as part of FinnGen study were computed using LD Score Regression
542	v1.0.1 using Finnish LD panel in FinnGen pipeline ⁴⁷ . The computation was based on the GWAS
543	summary statistics previously obtained using Regenie for each phenotype. We used the Benjamini-
544	Yekutieli method to control FDR of genetic correlation at level 0.05. Genetic correlation between
545	groups of phenotypes was approximated as the average of all the pair-wise genetic correlations
546	between the groups.

547

548 HLA and blood group imputation

The alleles of the classical HLA genes, *HLA-A*, *-C*, *-B*, *-DRB1*, *DRB3-5*, *-DQA1*, *-DQB1*, and *-DPB1*, had
been previously imputed at four-field resolution (i.e., defining protein sequence variation) in
FinnGen using HIBAG⁴⁹ algorithm with population-specific refence panel as reported earlier⁵⁰. The
dosage value of each HLA-allele was used in downstream analyses. Altogether 37 Red Blood cell, *RBC*, antigens in 14 different blood group systems were imputed using random forest models as
described by Hyvärinen et al⁵¹. After imputation, *P1*, *A1* and *A2* antigens were excluded from

555	downstream analyses due to uncertain frequency at the population level. In addition, blood group
556	antigens HrS and HrB, occurring mainly in African population, are in high correlation with blood
557	group antigen <i>e</i> and have low clinical significance (consultation with expert at Finnish Red Cross
558	Blood Service), hence they were excluded from further analyses. After imputation, the samples were
559	filtered based on the posterior probability, PP, value; samples with PP < 0.5 were considered as
560	antigen negative and samples with PP \ge 0.5 were considered as antigen positive. Altogether 13
561	individuals were excluded from downstream blood group related analyses due to all PP values in
562	ABO being < 0.5.
563	

564 pQTL

Protein quantitative trait loci, pQTL, analysis had been previously performed in FinnGen^{47,52} with
multiplex antibody-based immunoassay and multiplex aptamer-based immunoassay, Olink and
SomaScan⁵³, respectively, to detect associations between genetic variants and measured protein
levels. We extracted the proteomics summary statistics data for the 41 fine-mapped and the five
MHC lead variants in the present study from both datasets, Olink and SomaScan, and filtered the
results for statistical significance at FDR < 0.05 level.

571 To evaluate the enrichment of the associated proteins in functional processes, we used STRING 572 interaction network and functional enrichment analysis tool³⁰.

573

574

575 Data Availability

576 FinnGen summary statistics are available at www.finngen.fi. Data supporting the current study are

577 available from the authors upon reasonable request and with permission of FinnGen.

- 578 The GWAS results for the blood donor phenotype are available at GWAS catalogue under accession
- 579 number XXXXX.

- 581 Code Availability
- 582 Code is available in GitHub XXXXXX
- 583
- 584
- 585 References
- 5861.Mitchell, R. Blood banks, biobanks, and the ethics of donation. *Transfusion* **50**, 1866–1869587(2010).
- 5882.Raivola, V., Snell, K., Helén, I. & Partanen, J. Attitudes of blood donors to their sample and589data donation for biobanking. *Eur. J. Hum. Genet.* **27**, 1659–1667 (2019).
- 5903.Raivola, V., Snell, K., Helen, I. & Partanen, J. Attitudes of blood donors to their sample and591data donation for biobanking. *Eur. J. Hum. Genet.* **27**, 1659–1667 (2019).
- Finnish Red Cross Blood Service donation eligibility.
 https://www.veripalvelu.fi/en/faq/?search=&category=eligibility.
- 5. Hu, X. *et al.* Additive and interaction effects at three amino acid positions in HLA-DQ and 595 HLA-DR molecules drive type 1 diabetes risk. *Nat. Genet.* **47**, 898–905 (2015).
- De Silvestri, A. *et al.* The Involvement of HLA Class II Alleles in Multiple Sclerosis: A Systematic
 Review with Meta-analysis. *Dis. Markers* 2019, 1409069 (2019).
- 598 7. Dendrou, C. A., Petersen, J., Rossjohn, J. & Fugger, L. HLA variation and disease. *Nat. Rev.*599 *Immunol.* 18, 325–339 (2018).
- 6008.Ritari, J., Koskela, S., Hyvärinen, K., FinnGen & Partanen, J. HLA-disease association and601pleiotropy landscape in over 235,000 Finns. Hum. Immunol. 83, 391–398 (2022).
- Atsma, F., Veldhuizen, I., Kort, W. De & Vegt, F. De. Healthy donor effect: its magnitude in
 health research among blood donors. *Transfusion* 51, 1820–1828 (2011).
- Marsh, W. L. & Redman, C. M. The Kell blood group system: a review. *Transfusion* **30**, 158–
 167 (1990).
- 606 11. Avent, N. D. & Reid, M. E. The Rh blood group system: a review. *Blood* **95**, 375–387 (2000).
- Levine, P. & Stetson, R. E. Landmark article July 8, 1939. An unusual case of intra-group
 agglutination. By Philip Levine and Rufus E Stetson. *JAMA* 251, 1316–1317 (1984).
- GIBLETT, E. R. A critique of the theoretical hazard of inter vs. intra-racial transfusion. *Transfusion* 1, 233–238 (1961).
- Stowell, S. R. & Stowell, C. P. Biologic roles of the ABH and Lewis histo-blood group antigens
 part II: thrombosis, cardiovascular disease and metabolism. *Vox Sang.* 114, 535–552 (2019).
- 15. Dahlén, T., Clements, M., Zhao, J., Olsson, M. L. & Edgren, G. An agnostic study of associations

614		between ABO and RhD blood group and phenome-wide disease risk. Elife 10, (2021).
615 616	16.	Ward, S. E., O'Sullivan, J. M. & O'Donnell, J. S. The relationship between ABO blood group, von Willebrand factor, and primary hemostasis. <i>Blood</i> 136 , 2864–2874 (2020).
617 618	17.	Clancy, J. <i>et al.</i> Blood donor biobank as a resource in personalised biomedical genetic research. <i>Eur. J. Hum. Genet.</i> (2024) doi:10.1038/s41431-023-01528-0.
619	18.	FinnGen. FinnGen Result Browser. https://r10.finngen.fi/ (2024).
620	19.	National Institutes of Health LDlink. https://ldlink.nih.gov/?tab=home.
621 622	20.	ISBT Blood Group Allele Tables. https://www.isbtweb.org/isbt-working-parties/rcibgt/blood- group-allele-tables.html.
623 624	21.	Li, S. & Schooling, C. M. A phenome-wide association study of ABO blood groups. <i>BMC Med.</i> 18 , 334 (2020).
625 626	22.	Kurki, M. I. <i>et al.</i> FinnGen provides genetic insights from a well-phenotyped isolated population. <i>Nature</i> 613 , 508–518 (2023).
627 628 629	23.	Toivonen, J., Allara, E., Castrén, J., di Angelantonio, E. & Arvas, M. The value of genetic data from 665,460 individuals in managing iron deficiency anaemia and suitability to donate blood. <i>Vox Sang.</i> 119 , 34–42 (2024).
630 631	24.	Kangastupa, P. <i>et al.</i> The prevalence of hemoglobin Tacoma in Finland detected by HbA1c capillary electrophoresis. <i>Scand. J. Clin. Lab. Invest.</i> 83 , 51–57 (2023).
632 633	25.	Karczewski, K. J. <i>et al.</i> The mutational constraint spectrum quantified from variation in 141,456 humans. <i>Nature</i> 581 , 434–443 (2020).
634	26.	Bowness, P. HLA-B27. Annu. Rev. Immunol. 33, 29–48 (2015).
635 636	27.	Sayers, E. W. <i>et al.</i> Database resources of the national center for biotechnology information. <i>Nucleic Acids Res.</i> 50 , D20–D26 (2022).
637 638	28.	Borgoño, C. A., Michael, I. P. & Diamandis, E. P. Human tissue kallikreins: physiologic roles and applications in cancer. <i>Mol. Cancer Res.</i> 2 , 257–280 (2004).
639 640	29.	Lazaratos, AM., Annis, M. G. & Siegel, P. M. GPNMB: a potent inducer of immunosuppression in cancer. <i>Oncogene</i> 41 , 4573–4590 (2022).
641 642 643	30.	Szklarczyk, D. <i>et al.</i> The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. <i>Nucleic Acids Res.</i> 51 , D638–D646 (2023).
644 645 646 647	31.	Simon, M. <i>et al.</i> A study of 609 HLA haplotypes marking for the hemochromatosis gene: (1) mapping of the gene near the HLA-A locus and characters required to define a heterozygous population and (2) hypothesis concerning the underlying cause of hemochromatosis-HLA associa. <i>Am. J. Hum. Genet.</i> 41 , 89–105 (1987).
648 649	32.	Simon, M., Bourel, M., Fauchet, R. & Genetet, B. Association of HLA-A3 and HLA-B14 antigens with idiopathic haemochromatosis. <i>Gut</i> 17 , 332 LP – 334 (1976).
650 651 652	33.	Linjama, T. <i>et al.</i> Extended HLA Haplotypes and Their Impact on DPB1 Matching of Unrelated Hematologic Stem Cell Transplant Donors. <i>Biol. Blood Marrow Transplant.</i> 25 , 1956–1964 (2019).
653	34.	Brown, J. H. et al. Three-dimensional structure of the human class II histocompatibility

654 antigen HLA-DR1. *Nature* **364**, 33–39 (1993).

- 655 35. Groot, H. E. *et al.* Genetically Determined ABO Blood Group and its Associations With Health 656 and Disease. *Arterioscler. Thromb. Vasc. Biol.* **40**, 830–838 (2020).
- Stowell, C. P. & Stowell, S. R. Biologic roles of the ABH and Lewis histo-blood group antigens
 Part I: infection and immunity. *Vox Sang.* 114, 426–442 (2019).
- Franchini, M., Favaloro, E. J., Targher, G. & Lippi, G. ABO blood group, hypercoagulability, and
 cardiovascular and cancer risk. *Crit. Rev. Clin. Lab. Sci.* 49, 137–149 (2012).
- 661 38. Che Yaacob, N. S., Islam, M. A., Alsaleh, H., Ibrahim, I. K. & Hassan, R. Alpha-hemoglobin662 stabilizing protein (AHSP): a modulatory factor in β-thalassemia. *Int. J. Hematol.* 111, 352–
 663 359 (2020).
- dos Santos, C. O. & Costa, F. F. AHSP and beta-thalassemia: a possible genetic modifier. *Hematology* 10, 157–161 (2005).
- Giardine, B. *et al.* Updates of the HbVar database of human hemoglobin variants and
 thalassemia mutations. *Nucleic Acids Res.* 42, D1063-9 (2014).
- Rutherford-Parker, N. J., Colby, J. M., Gehrie, E. A. & Booth, G. S. Unrecognized Hemoglobin
 Variants in the Donor Blood Supply Are Detectable in the Transfused Population. *Am. J. Clin. Pathol.* 154, 494–498 (2020).
- 671 42. FinnGen. FinnGen Documentation of data release.
 672 https://finngen.gitbook.io/documentation/ (2024).
- 673 43. R Core Team. https://www.r-project.org/.
- 674 44. R studio. https://www.rstudio.com/.
- 67545.Benjamini, Y. & Yekutieli, D. The control of the false discovery rate in multiple testing under676dependency. Ann. Stat. 29, 1165–1188 (2001).
- 46. Mbatchou, J. *et al.* Computationally efficient whole-genome regression for quantitative and
 binary traits. *Nat. Genet.* 53, 1097–1103 (2021).
- 679 47. FinnGen gitbook. https://github.com/FINNGEN/.
- 48. Wang, G., Sarkar, A., Carbonetto, P. & Stephens, M. A Simple New Approach to Variable
 681 Selection in Regression, with Application to Genetic Fine Mapping. *J. R. Stat. Soc. Ser. B Stat.*682 *Methodol.* 82, 1273–1300 (2020).
- 49. Zheng, X. *et al.* HIBAG HLA genotype imputation with attribute bagging. *Pharmacogenomics J.* 14, 192–200 (2014).
- 68550.Ritari, J. *et al.* Increasing accuracy of HLA imputation by a population-specific reference panel686in a FinnGen biobank cohort. NAR Genomics Bioinforma. 2, (2020).
- 51. Hyvärinen, K. *et al.* A machine-learning method for biobank-scale genetic prediction of blood
 group antigens. *PLoS Comput. Biol.* 20, e1011977 (2024).
- 52. FinnGen. FinnGen Documentation. https://finngen.gitbook.io/finngen-handbook (2024).
- 53. Suhre, K., McCarthy, M. I. & Schwenk, J. M. Genetics meets proteomics: perspectives for large
 population-based studies. *Nat. Rev. Genet.* 22, 19–37 (2021).

694

695 Acknowledgements:

- 696 We want to acknowledge the participants and investigators of FinnGen study. The FinnGen project is
- 697 funded by two grants from Business Finland (HUS 4685/31/2016 and UH 4386/31/2016) and the
- 698 following industry partners: AbbVie Inc., AstraZeneca UK Ltd, Biogen MA Inc., Bristol Myers Squibb
- 699 (and Celgene Corporation & Celgene International II Sàrl), Genentech Inc., Merck Sharp & Dohme
- 700 LCC, Pfizer Inc., GlaxoSmithKline Intellectual Property Development Ltd., Sanofi US Services Inc.,
- 701 Maze Therapeutics Inc., Janssen Biotech Inc, Novartis Pharma AG, and Boehringer Ingelheim
- 702 International GmbH. Following biobanks are acknowledged for delivering biobank samples to
- 703 FinnGen: Auria Biobank (<u>www.auria.fi/biopankki</u>), THL Biobank (<u>www.thl.fi/biobank</u>), Helsinki
- 704 Biobank (www.helsinginbiopankki.fi), Biobank Borealis of Northern Finland
- 705 (https://www.ppshp.fi/Tutkimus-ja-opetus/Biopankki/Pages/Biobank-Borealis-briefly-in-
- 706 English.aspx), Finnish Clinical Biobank Tampere (www.tays.fi/en-
- 707 US/Research and development/Finnish_Clinical_Biobank_Tampere), Biobank of Eastern Finland
- 708 (www.ita-suomenbiopankki.fi/en), Central Finland Biobank (www.ksshp.fi/fi-FI/Potilaalle/Biopankki),
- 709 Finnish Red Cross Blood Service Biobank (<u>www.veripalvelu.fi/verenluovutus/biopankkitoiminta</u>),
- 710 Terveystalo Biobank (www.terveystalo.com/fi/Yritystietoa/Terveystalo-Biopankki/Biopankki/) and
- 711 Arctic Biobank (<u>https://www.oulu.fi/en/university/faculties-and-units/faculty-medicine/northern-</u>
- 712 finland-birth-cohorts-and-arctic-biobank). All Finnish Biobanks are members of BBMRI.fi
- 713 infrastructure (<u>www.bbmri.fi</u>). Finnish Biobank Cooperative -FINBB (<u>https://finbb.fi/</u>) is the
- coordinator of BBMRI-ERIC operations in Finland. The Finnish biobank data can be accessed through
- the Fingenious[®] services (<u>https://site.fingenious.fi/en/</u>) managed by FINBB.
- 716 In addition, we want to acknowledge Dr Katri Haimila for her valuable advice with red cell antigen
- 717 immunogenetics, Dr Kati Hyvärinen for her expertise and kind help with red cell antigen imputation
- and the personnel of Blood Service Biobank for their kind help and support for the study.

719

720 Author Contributions

- 721 Original study concept by JC and JR. Genetic and statistical analysis of the study: JC, JT, MA and JR.
- 722 Visualization: JC, JT and JR. Medical expertise: JL. FinnGen: data curation and resources. Procedures
- 723 in the Blood Service Biobank: SK. Original manuscript: JC. JC, JT, JL, SK, JP, FinnGen, MA, JR read,
- commented, and approved the final manuscript.
- 725 Competing Interests
- 726 The authors declare no competing interests.